BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing
- PMID: 9333265
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing
Abstract
Context: A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer. However, knowledge regarding all possible mutations and the relationship between risk factors and mutations is incomplete.
Objectives: To identify BRCA1 mutations and to determine factors that best predict presence of a deleterious BRCA1 mutation in patients with breast and/or ovarian cancer.
Design: A complete sequence analysis of the BRCA1 coding sequence and flanking intronic regions was performed in 798 women in a collaborative effort involving institutions from the United States, Italy, Germany, Finland, and Switzerland.
Participants: Institutions selected 798 persons representing families (1 person for each family) thought to be at elevated a priori risk of BRCA1 mutation due to potential risk factors, such as multiple cases of breast cancer, early age of breast cancer diagnosis, and cases of ovarian cancer. No participant was from a family in which genetic markers showed linkage to the BRCA1 locus.
Major outcome measures: Sequence variants detected in this sample are presented along with analyses designed to determine predictive characteristics of those testing positive for BRCA1 mutations.
Results: In 102 women (12.8%), clearly deleterious mutations were detected. Fifty new genetic alterations were found including 24 deleterious mutations, 24 variants of unknown significance, and 2 rare polymorphisms. In a subset of 71 Ashkenazi Jewish women, only 2 distinct deleterious mutations were found: 185delAG in 17 cases and 5382insC in 7 cases. A bias in prior reports for mutations in exon 11 was revealed. Characteristics of a patient's specific diagnosis (unilateral or bilateral breast cancer, with or without ovarian cancer), early age at diagnosis, Ashkenazi Jewish ethnicity, and family history of cancer were positively associated with the probability of her carrying a deleterious BRCA1 mutation.
Conclusions: Using logistic regression analysis, we provide a method for evaluating the probability of a woman's carrying a deleterious BRCA1 mutation for a wide range of cases, which can be an important tool for clinicians as they incorporate genetic susceptibility testing into their medical practice.
Comment in
-
Family history and genetic risk factors: forward to the future.JAMA. 1997 Oct 15;278(15):1284-5. JAMA. 1997. PMID: 9333273 No abstract available.
Similar articles
-
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.N Engl J Med. 1997 May 15;336(20):1409-15. doi: 10.1056/NEJM199705153362002. N Engl J Med. 1997. PMID: 9145677
-
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.Breast Cancer Res Treat. 2004 Nov;88(2):177-86. doi: 10.1007/s10549-004-0593-8. Breast Cancer Res Treat. 2004. PMID: 15564800
-
Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.Neoplasma. 2006;53(2):97-102. Neoplasma. 2006. PMID: 16575464
-
Role of BRCA1 mutation screening in the management of familial ovarian cancer.Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.
-
Genetic susceptibility testing for breast and ovarian cancer: a progress report.J Am Med Womens Assoc (1972). 1997 Winter;52(1):22-7. J Am Med Womens Assoc (1972). 1997. PMID: 9033168 Review.
Cited by
-
Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y. World J Surg. 2012. PMID: 22290208 Free PMC article.
-
Ethical issues raised by genetic testing with oligonucleotide microarrays.Mol Biotechnol. 2003 Feb;23(2):127-38. doi: 10.1385/MB:23:2:127. Mol Biotechnol. 2003. PMID: 12632697 Review.
-
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population.Breast Cancer Res Treat. 2007 Dec;106(2):297-304. doi: 10.1007/s10549-006-9493-4. Epub 2007 Feb 15. Breast Cancer Res Treat. 2007. PMID: 17972177 Free PMC article.
-
Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.J Med Genet. 2003 Jul;40(7):503-10. doi: 10.1136/jmg.40.7.503. J Med Genet. 2003. PMID: 12843322 Free PMC article.
-
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.Br J Cancer. 2001 Mar 2;84(5):704-8. doi: 10.1054/bjoc.2000.1626. Br J Cancer. 2001. PMID: 11237395 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous